AI in Medicine: How Seegnal is Setting a New Global Standard for Patient Safety

CALGARY, AB – February 02, 2026 – In a significant move that underscores the growing integration of artificial intelligence into frontline healthcare, Canadian-listed tech firm Seegnal Inc. (TSXV: SEGN) has deepened its partnership with Tel Aviv Sourasky Medical Center, one of Israel's most prestigious and largest hospitals. The expanded deployment of Seegnal's Prescription Intelligence Platform is not just a business deal; it represents a major validation of a new, patient-specific standard for medication safety that could have ripple effects across the globe.

Effective January 1, 2026, the agreement solidifies the use of Seegnal's AI-driven system across multiple departments at Sourasky, a facility that treats over 1.5 million patients annually. The platform will now be a daily tool for approximately 1,200 clinicians and 2,050 medical team members, embedding advanced decision support directly into their routine workflows. This expansion, which runs until the end of 2027 with an option to extend through 2031, signals a profound confidence in a technology that promises to solve one of modern medicine's most persistent and dangerous problems: adverse drug effects (ADEs).

"Sourasky Medical Center represents one of the most advanced clinical environments within public health systems worldwide," said Elad Bibi-Aviv, Chief Executive Officer of Seegnal, in a statement. "The expansion of our deployment reflects strong confidence in the clinical, operational, and economic value Seegnal delivers at scale."

Beyond the Alert: The Science of Patient-Specific Intelligence

For decades, clinicians have been grappling with "alert fatigue"—a desensitization to the constant barrage of warnings from electronic health record (EHR) systems. Traditional clinical decision support (CDS) tools, while well-intentioned, often rely on simplistic drug-to-drug interaction (DDI) checks, generating a high volume of low-relevance alerts that are frequently overridden and ignored. This digital noise can paradoxically increase risk by burying critical warnings in a sea of trivial ones.

Seegnal's platform introduces a paradigm shift. Instead of generic warnings, it creates a holistic, patient-specific risk profile in real-time. The system analyzes a comprehensive array of individual patient data far beyond the prescriptions themselves, including laboratory results, comorbidities, age, gender, renal function, vital signs, allergies, and even the context of polypharmacy (a patient's use of multiple medications). The result is a system that filters out the noise to deliver highly precise and actionable insights.

Independent research validates these claims. A 2021 comparative study published in the journal Drug Safety found that Seegnal's platform triggered 94% fewer alerts than the legacy CDS system within Epic, a leading EHR provider. More importantly, the study highlighted that Seegnal demonstrated significantly higher sensitivity and specificity, correctly identifying risks that the other system missed. This dramatic reduction in alerts—with a reported accuracy of up to 98%—allows clinicians to focus on the warnings that truly matter, saving time and, more critically, preventing patient harm.

This level of precision transforms the technology from a potential nuisance into a trusted clinical ally, empowering doctors to make more informed decisions at the point of care without disrupting their workflow.

The Economic Case for Smarter Prescribing

While the primary benefit is enhanced patient safety, the expanded deployment at Sourasky also highlights the powerful economic case for investing in prescription intelligence. Adverse drug effects are not only a leading cause of injury and death but also a massive financial drain on healthcare systems, leading to extended hospital stays, readmissions, and costly interventions.

Seegnal's own data, supported by a study in The American Journal of Pharmacy Benefits, reports that institutions using its platform have seen measurable reductions in medication-related adverse events and avoidable hospitalizations. Specifically, the company cites a 5.6% reduction in drug-event related hospitalizations and a 1.5% decrease in total drugs dispensed. For a large medical center like Sourasky, these percentages translate into substantial cost savings and a more efficient allocation of critical resources.

By improving prescribing efficiency and reducing unnecessary medication use, the platform directly supports the global shift toward value-based care, where reimbursement is tied to patient outcomes rather than the volume of services provided. This proven return on investment is a key reason why Sourasky Medical Center now serves as a global reference site for Seegnal. The hospital actively showcases its large-scale, real-world deployment to international medical centers, providing a proven model for how to improve clinical governance and financial sustainability simultaneously.

"This deployment demonstrates that patient-specific prescribing intelligence can improve safety and efficiency while supporting sustainable economics for large medical centers," added Mr. Bibi-Aviv.

From Tel Aviv to the World: A National Standard Paves the Way

The partnership's significance extends far beyond the walls of a single hospital. It is emblematic of a national strategy that has positioned Israel at the forefront of digital health innovation. In a powerful endorsement, Israel's Ministry of Health has officially adopted Seegnal's patient-specific approach as the new standard of care for governmental hospitals. This top-down validation provides a powerful tailwind for the company and sets a precedent for other national health systems to follow.

With a secure foothold and a proven track record in its home market—where over 15,000 clinicians already use the platform daily—Seegnal is leveraging this success for international expansion. The company is actively marketing its SaaS-based solution in the United Arab Emirates, the United Kingdom, the United States, and Poland.

The success story at Sourasky Medical Center serves as Seegnal's most compelling calling card. It is a tangible demonstration that it is possible to move beyond the theoretical promise of AI in medicine to a practical, scalable, and economically viable solution. As healthcare systems worldwide continue to face the dual pressures of improving patient outcomes and managing costs, this blueprint for intelligent, patient-centric care developed in Israel is poised to become a new global standard.